Molecule Group (LON:MOL) Stock: Insider Brendan O’Brien Purchases 23,200 Shares

Key Points

  • Insider Brendan O’Brien purchased 23,200 Molecule Group shares at an average price of GBX 212, for a total investment of £49,184.
  • Molecule Group shares opened at GBX 202, down 2.4%, with the stock near its 52-week low of GBX 202 and a market capitalization of approximately £55.1 million.
  • Canaccord Genuity maintained a Buy rating and a GBX 308 price target; the stock has a consensus Buy rating and target price of GBX 308 from one analyst.

Molecule Group (LON:MOL - Get Free Report) insider Brendan O’Brien purchased 23,200 shares of the business's stock in a transaction on Monday, October 12th. The shares were purchased at an average price of GBX 212 per share, with a total value of £49,184.

Molecule Group Stock Down 2.4%

LON MOL opened at GBX 202 on Wednesday. Molecule Group has a 52 week low of GBX 202 and a 52 week high of GBX 220. The stock has a market cap of £55.10 million and a PE ratio of -10.31.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group restated a "buy" rating and set a GBX 308 target price on shares of Molecule Group in a research report on Tuesday, September 29th. One analyst has rated the stock with a Buy rating. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of GBX 308.

Read Our Latest Research Report on Molecule Group

See Also

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Molecule Group?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Molecule Group and related companies.
From Our Partners
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles